137 related articles for article (PubMed ID: 36352160)
1. Inhibition of BRD4 enhanced the tumor suppression effect of dasatinib in gastric cancer.
Shen H; Hu X; Yang X; Chen J; Fu Y; He H; Shi Y; Zeng R; Chang W; Zheng S
Med Oncol; 2022 Nov; 40(1):9. PubMed ID: 36352160
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Bromodomain and Extraterminal Domain is Associated with Progression, Metastasis and Unfavorable Outcomes: Highlighting Prognostic and Therapeutic Value of the BET Protein Family in Gastric Cancer.
Fard SS; Kouchaki S; Salimian Z; Sotoudeh M; Mousavi SA; Alimoghaddam K; Ghaffari SH
Anticancer Agents Med Chem; 2023; 23(7):794-806. PubMed ID: 36284375
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of BRD4 in Gastric Cancer and its Clinical Significance as a Novel Therapeutic Target.
Zhang M; Huang H; Wei M; Sun M; Deng G; Hu S; Wang H; Gong Y
Curr Cancer Drug Targets; 2024; 24(2):167-177. PubMed ID: 37282642
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the bromodomain and extra-terminal family of epigenetic regulators as a promising therapeutic approach for gastric cancer.
Kang SK; Bae HJ; Kwon WS; Kim TS; Kim KH; Park S; Yu SY; Hwang J; Park J; Chung HC; Rha SY
Cell Oncol (Dordr); 2021 Dec; 44(6):1387-1403. PubMed ID: 34791636
[TBL] [Abstract][Full Text] [Related]
5. Bromodomain protein 4 is a novel predictor of survival for gastric carcinoma.
Zhu Y; Yang W; Ji G; Lin N; Wu W; Xiong P; Zheng C; Yan L; Wan P; Wang Y
Oncotarget; 2017 May; 8(19):31092-31100. PubMed ID: 28415703
[TBL] [Abstract][Full Text] [Related]
6. BRD4 promotes tumor growth and epithelial-mesenchymal transition in hepatocellular carcinoma.
Zhang P; Dong Z; Cai J; Zhang C; Shen Z; Ke A; Gao D; Fan J; Shi G
Int J Immunopathol Pharmacol; 2015 Mar; 28(1):36-44. PubMed ID: 25816404
[TBL] [Abstract][Full Text] [Related]
7. BRD4 promotes gastric cancer progression through the transcriptional and epigenetic regulation of c-MYC.
Ba M; Long H; Yan Z; Wang S; Wu Y; Tu Y; Gong Y; Cui S
J Cell Biochem; 2018 Jan; 119(1):973-982. PubMed ID: 28681984
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of dual BRD4/Src inhibitors for treatment of triple-negative breast cancer.
Wang Y; Huang A; Chen L; Sun F; Zhao M; Zhang M; Xie Y; Xu S; Li M; Hong L; Li G; Wang R
Eur J Med Chem; 2024 Jan; 264():116009. PubMed ID: 38070430
[TBL] [Abstract][Full Text] [Related]
9. Berbamine Suppresses the Growth of Gastric Cancer Cells by Inactivating the BRD4/c-MYC Signaling Pathway.
Li H; Luo K; Yang Z; Chen M; Yang X; Wang J; Ying Y; Wu D; Wang Q
Drug Des Devel Ther; 2022; 16():129-141. PubMed ID: 35046638
[TBL] [Abstract][Full Text] [Related]
10. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
11. DSC2 Suppresses the Metastasis of Gastric Cancer through Inhibiting the BRD4/Snail Signaling Pathway and the Transcriptional Activity of
Sun C; Wang L; Du DD; Ji JB; Yang XX; Yu BF; Shang PF; Guo XL
Oxid Med Cell Longev; 2022; 2022():4813571. PubMed ID: 36120591
[TBL] [Abstract][Full Text] [Related]
12. Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.
Choi KM; Cho E; Bang G; Lee SJ; Kim B; Kim JH; Park SG; Han EH; Chung YH; Kim JY; Kim E; Kim JY
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291786
[TBL] [Abstract][Full Text] [Related]
13. Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma.
Song S; Li Y; Xu Y; Ma L; Pool Pizzi M; Jin J; Scott AW; Huo L; Wang Y; Lee JH; Bhutani MS; Weston B; Shanbhag ND; Johnson RL; Ajani JA
Mol Oncol; 2020 Jun; 14(6):1410-1426. PubMed ID: 32175692
[TBL] [Abstract][Full Text] [Related]
14. BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor.
Zhang P; Li R; Xiao H; Liu W; Zeng X; Xie G; Yang W; Shi L; Yin Y; Tao K
Int J Biol Sci; 2019; 15(9):1942-1954. PubMed ID: 31523195
[No Abstract] [Full Text] [Related]
15. Circular RNA circ-DONSON facilitates gastric cancer growth and invasion via NURF complex dependent activation of transcription factor SOX4.
Ding L; Zhao Y; Dang S; Wang Y; Li X; Yu X; Li Z; Wei J; Liu M; Li G
Mol Cancer; 2019 Mar; 18(1):45. PubMed ID: 30922402
[TBL] [Abstract][Full Text] [Related]
16. BRD4 promotes the stemness of gastric cancer cells via attenuating miR-216a-3p-mediated inhibition of Wnt/β-catenin signaling.
Song H; Shi L; Xu Y; Xu T; Fan R; Cao M; Xu W; Song J
Eur J Pharmacol; 2019 Jun; 852():189-197. PubMed ID: 30876979
[TBL] [Abstract][Full Text] [Related]
17. BRD4 regulates key transcription factors that drive epithelial-mesenchymal transition in castration-resistant prostate cancer.
Shafran JS; Jafari N; Casey AN; Győrffy B; Denis GV
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):268-277. PubMed ID: 32690869
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-4651 targets bromodomain-containing protein 4 to inhibit non-small cell lung cancer cell progression.
Zheng J; Zhang Y; Cai S; Dong L; Hu X; Chen MB; Zhu YH
Cancer Lett; 2020 Apr; 476():129-139. PubMed ID: 32081805
[TBL] [Abstract][Full Text] [Related]
19. Elevated HOXA1 expression correlates with accelerated tumor cell proliferation and poor prognosis in gastric cancer partly via cyclin D1.
Yuan C; Zhu X; Han Y; Song C; Liu C; Lu S; Zhang M; Yu F; Peng Z; Zhou C
J Exp Clin Cancer Res; 2016 Jan; 35():15. PubMed ID: 26791264
[TBL] [Abstract][Full Text] [Related]
20. BATF2 inhibits chemotherapy resistance by suppressing AP-1 in vincristine-resistant gastric cancer cells.
Yang W; Zhao S; Wu B; Xu J; Wu Z; Guo J; Zeng R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1279-1288. PubMed ID: 31549215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
